Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rocilinostat

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract HDAC6 is a protein involved in cancer, neurodegenerative disease and inflammatory disorders. To date, the full three… Expand
Is this relevant?
2017
2017
Histone deacetylases (HDACs) are a family of proteins involved in the deacetylation of histones and other non-histones substrates… Expand
Is this relevant?
2017
2017
A sensitive and rapid LC-MS/MS method was developed and validated for the simultaneous quantitation of four HDAC inhibitors… Expand
Is this relevant?
2017
2017
Objective: To investigate the protective effect of ACY1215 (Rocilinostat), a histone deacetylase inhibitor, against brain edema… Expand
Is this relevant?
2016
2016
Histone deacetylases (HDACs) catalyze the cleavage of acetyl groups from N-acetyl-lysine residues of histones and non-histone… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2016
2016
A highly sensitive, specific and rapid LC-ESI-MS/MS method has been developed and validated for the quantification of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Review
2014
Review
2014
In spite of significant advances in the management of multiple myeloma (MM), the disease remains incurable and nearly all… Expand
Is this relevant?
2014
2014
Background and Purpose. Histone deacetylase (HDAC) inhibitors are emerging as an exciting new therapeutic option for lymphoid… Expand
Is this relevant?
2012
2012
Abstract 4061 Introduction The rate of relapse in multiple myeloma (MM) remains high despite novel therapies such as the… Expand
Is this relevant?
2012
2012
Abstract 1650 The emergence of epigenetic therapies has identified histone deacetylase(HDAC) inhibitors as effective therapeutic… Expand
Is this relevant?